WO1995029895A1 - Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents - Google Patents

Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents Download PDF

Info

Publication number
WO1995029895A1
WO1995029895A1 PCT/EP1995/001347 EP9501347W WO9529895A1 WO 1995029895 A1 WO1995029895 A1 WO 1995029895A1 EP 9501347 W EP9501347 W EP 9501347W WO 9529895 A1 WO9529895 A1 WO 9529895A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
bis
compound
formula
dibenz
Prior art date
Application number
PCT/EP1995/001347
Other languages
English (en)
French (fr)
Inventor
Miguel Fernandez Brana
Jose Maria Castellano Berlanga
Cynthia Romerdahl
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Priority to EP95916636A priority Critical patent/EP0757676A1/en
Priority to AU23065/95A priority patent/AU2306595A/en
Priority to JP7527954A priority patent/JPH09512539A/ja
Publication of WO1995029895A1 publication Critical patent/WO1995029895A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to novel bis-l,2-dihydro-3H-dibenzisoqui- noline-l,3-diones and their salts, processes for their prepara ⁇ tion, pharmaceutical compositions containing them and methods of using them to treat malignancies, mainly human solid tumor carci- nomas.
  • the present invention relates to bis-l,2-dihydro-3H-dibenzisoqui- noline-l,3-diones of the formula I
  • X, X', Y, and Y' are identical or different and are each H, N0 2 , NH , Ci-Ce-alkylamino, di-C ⁇ -C 6 alkylamino, NH-C ⁇ _ 6 -acyl, OH, Ci-H ⁇ -alkoxy, halogen, trihalomethyl, Ci-C ⁇ -alkyl, formyl, Ci-C ⁇ -alkylcarbonyl, ureyl, Ci-C ⁇ -alkylureyl and A is a C 4 -C ⁇ -bridge which is interrupted at one, two or three points by a secondary or tertiary amino group, where two nitrogen atoms may additionally be bonded to one another by a C ⁇ - 4 -alkylene group and the salts thereof with physiologically tolerated acids.
  • One class of compounds of the present invention is bis-l,2-di- hydro-3H-dibenzisoquinoline-l,3-diones of the formula I in which at least one of X, X', Y, and Y' are not H, i.e., wherein X, X', Y, and Y' are identical or different and are selected from the group consisting of N0 2 , NH2» NH-lower acyl, Ci-e-alkylamino, di-C ⁇ - 6 -alkylamino, OH, C ⁇ _ 6 -alkoxy, halogen, trihalomethyl,
  • Ci-g-alkyl, formyl, Ci-e-alkylcarbonyl, ureyl, and C ⁇ - 6 -alkylureyl It is currently preferred in various embodiments of this class for none of X, X', Y, and Y' to be N0 2 .
  • One subclass of the foregoing is bis-l,2-dihydro-3H-dibenzoiso- quinoline-1,3-diones of the formula I wherein at least one of X, Y', Y and Y' is NH 2 , NH-lower acyl, C ⁇ - 6 -alkylamino or di-C ⁇ -6-alkylamino.
  • This class includes, among others, compounds of the formula I in which X and Y are H; X' and Y' are NHCOCH 3 ; and -A- is -CH(CH 3 ) -CH 2 -NH-CH 2 -CH 2 -NH-CH 2 -CH(CH 3 ) - or -(CH 2 ) 2 -NH-(CH 2 ) 3 -NH- (CH 2 ) 2 -.
  • Another class of compounds of the present invention is bis-l,2-dihydro-3-H-dibenzisoquinoline-l,3-diones of the for ⁇ mula I in which A is
  • C n , C n' , and C n - are identical or different and are each C ⁇ - 4 -alkylene radicals and R and R'are H, C ⁇ - 4 -alkyl, benzyl, phenyl, or phenyl substituted by a halogen atom or a C ⁇ - -alkyl group or an amino group.
  • R and R' are as previously defined. These compounds in- elude those in which X and X' and R and R' are all H.
  • Hal means a halogen atom, preferably bromine; 3. - if A is interrupted by two nitrogen atoms - by reacting a compound of the formula IV with a diamine of the formula V:
  • B plus D are alkylene residues so that 2 B plus D contain 4 to 12 carbon atoms.
  • Reaction 1 is performed by reacting the compound II with a half equivalent of a polyamine of the formula III in an organic sol ⁇ vent such as alcohols (especially ethanol) , acetone, DMSO, THF, DMF, dioxane, aromatic hydrocarbons (especially toluene) , or any inert solven .
  • an organic sol ⁇ vent such as alcohols (especially ethanol) , acetone, DMSO, THF, DMF, dioxane, aromatic hydrocarbons (especially toluene) , or any inert solven .
  • the temperature of the reaction should be between -20°C and the boiling temperature of the solvent. Fairly high tem- peratures are preferred.
  • Reactions 2 and 3 are performed under the same conditions, but in the presence of a base.
  • the final product is filtered off or the reaction mixture is evaporated to dryness under reduced pressure and the residue is purified in conventional manner by crystallization or chromato- graphy.
  • the starting compounds II-VI can be prepared by methods known from the literature, or they are commercial products.
  • the bis-l,2-dihydro-3H-dibenzoisoquinoline-l,3-diones so obtained are used per se, or they can be acidified with the appropriate mineral or organic acid to produce a pharmaceutically acceptable salt, e.g. the methanesulfonate or the acetate salt, which can be recovered by filtration.
  • Salts of the free base can also be pre ⁇ pared by acidifying a suspension of the free base in ethyl alco ⁇ hol, dichloromethane, ether, etc. with the appropriate mineral or organic acid and collecting by filtration the solid thus formed.
  • Other acids for salt formation are known from the art, see e.g., Braia et al., U.S. Patent 4,874,883.
  • the present invention further encompasses pharmaceutical composi- 5 tions containing a tumor-inhibiting compound according to the in ⁇ vention together with a pharmaceutically acceptable carrier. It also relates to methods for treating tumors in mammals comprising administration of a tumor-inhibiting amount of a compound accord ⁇ ing to the invention to a mammal with such a tumor.
  • the compounds 0 according to the invention may be formulated into pharmaceutical compositions and administered to patients using conventional materials and methods such as are described in Brafia et al., US 4,874,883 and US 5,206,249 (the contents of both of which are hereby incorporated herein by reference) . See especially
  • the compounds according to the invention have cytotoxic activity useful in the treatment of various cancers. These compounds can be evaluated for relative efficacy in in vitro and in vivo models
  • the new compounds exhibit better properties than prior art compounds with regard to activity, toxicity and/or solubility.
  • Cytotoxicity may be measured using standard methodology for ad ⁇ herent cell lines such as the microculture tetrazolium assay (MTT) . Details of this assay have been published Cancer Research
  • the MTT dye is added (50 ⁇ l of 3 mg/ l solution of 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in saline). This mixture is incubated at 37°C for 5 hours, and then
  • the concentration of test compound which gives a T/C of 50% growth inhibition is designated as the IC 50 .
  • Compounds according to the invention may be further tested in any of the various preclinical assays for in vivo activity which are indicative of clinical utility.
  • Such assays may be conducted with nude mice into which tumor tissue, preferably of human origin, has been transplanted ("xenografted") , as is well known in this field.
  • Test compounds are evaluated for their antitumor efficacy following administration to the xenograft-bearing mice.
  • mice which have been grown in athymic nude mice are transplanted into new recipient animals, using tu ⁇ mor fragments which are about 50 mg in size.
  • the day of trans- plantation is designated as day 0.
  • mice are injected intravenously or intraperitoneally with the test compounds, in groups of 5-10 mice per dose.
  • the compounds are ad ⁇ ministered daily for 5 days, 10 days or 15 days, at doses from 10-100 mg/kg body weight.
  • Tumor volumes are calculated using the diameters measured twice weekly. Tumor volumes whose diameters are measured with Vernier calipers are calculated by the formula:
  • Mean tumor volumes are calculated for each treatment group, and T/C values determined for each group relative to the untreated control tumors.
  • the data may be evaluated as follows. A T/C value of 1.0 or greater indicates that the compound had no effect on tumor growth, while values ⁇ 1.0 indicate some reduction in tumor mass. Values of 0.15-0.49 may be considered to reflect moderate activity, ⁇ 0.01-0.14 good to excellent activity. Outstanding ac ⁇ tivity indicates a compound which provides complete regression of tumor material (no visible tumor mass following therapy) . Compounds yielding T/C values > 0.50 are considered inactive.
  • the invention can be further understood by referring to the fol ⁇ lowing examples, in which parts and percentages are by weight un ⁇ less otherwise specified.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PCT/EP1995/001347 1994-04-28 1995-04-12 Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents WO1995029895A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95916636A EP0757676A1 (en) 1994-04-28 1995-04-12 Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents
AU23065/95A AU2306595A (en) 1994-04-28 1995-04-12 Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents
JP7527954A JPH09512539A (ja) 1994-04-28 1995-04-12 ジヒドロジベンゾ（ｄｅ，ｈ）イソキノリン誘導体および抗癌剤としての該誘導体の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23399894A 1994-04-28 1994-04-28
US08/233,998 1994-04-28

Publications (1)

Publication Number Publication Date
WO1995029895A1 true WO1995029895A1 (en) 1995-11-09

Family

ID=22879465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001347 WO1995029895A1 (en) 1994-04-28 1995-04-12 Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents

Country Status (11)

Country Link
EP (1) EP0757676A1 (enrdf_load_stackoverflow)
JP (1) JPH09512539A (enrdf_load_stackoverflow)
CN (1) CN1092185C (enrdf_load_stackoverflow)
AU (1) AU2306595A (enrdf_load_stackoverflow)
CA (1) CA2188833A1 (enrdf_load_stackoverflow)
HR (1) HRP950250A2 (enrdf_load_stackoverflow)
IL (1) IL113415A (enrdf_load_stackoverflow)
SG (1) SG73418A1 (enrdf_load_stackoverflow)
TW (1) TW307764B (enrdf_load_stackoverflow)
WO (1) WO1995029895A1 (enrdf_load_stackoverflow)
ZA (1) ZA953379B (enrdf_load_stackoverflow)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
WO2008007262A3 (en) * 2006-06-19 2008-08-14 Univ Do Porto Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101638389B (zh) * 2008-03-03 2012-09-05 河南大学 一种含萘酰亚胺结构的多胺衍生物及其制备方法和应用
CN117074567B (zh) * 2023-08-25 2025-06-27 四川汇宇制药股份有限公司 高效液相色谱法检测氨磷汀中间体纯度及其有关物质的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125439A2 (en) * 1983-04-01 1984-11-21 Warner-Lambert Company 3,6-Disubstituted-1,8-naphthalimides and methods for their production and use
EP0281902A1 (de) * 1987-03-10 1988-09-14 Knoll Ag Bis-naphthalimide, ihre Herstellung und Verwendung
WO1992000281A1 (en) * 1990-06-26 1992-01-09 Research Corporation Technologies, Inc. 1,2-dihydro-3h-dibenzisoquinoline-1,3-dione anticancer agents
WO1994006771A1 (en) * 1992-09-11 1994-03-31 Research Corporation Technologies, Inc. 1,2 DIHYDRO-3-H-DIBENZ(de,h) ISOQUINOLINE 1,3 DIONE AND THEIR USE AS ANTICANCER AGENTS
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125439A2 (en) * 1983-04-01 1984-11-21 Warner-Lambert Company 3,6-Disubstituted-1,8-naphthalimides and methods for their production and use
EP0281902A1 (de) * 1987-03-10 1988-09-14 Knoll Ag Bis-naphthalimide, ihre Herstellung und Verwendung
WO1992000281A1 (en) * 1990-06-26 1992-01-09 Research Corporation Technologies, Inc. 1,2-dihydro-3h-dibenzisoquinoline-1,3-dione anticancer agents
WO1994006771A1 (en) * 1992-09-11 1994-03-31 Research Corporation Technologies, Inc. 1,2 DIHYDRO-3-H-DIBENZ(de,h) ISOQUINOLINE 1,3 DIONE AND THEIR USE AS ANTICANCER AGENTS
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SALAH M. SAMI ET AL: "2-Substituted 1,2-dihydro-3H-dibenzo[de,h]isoquinoline-1,3-diones.A new class of antitumor agent", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 6, 19 March 1993 (1993-03-19), WASHINGTON US, pages 765 - 770 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US7307080B2 (en) 1999-09-01 2007-12-11 Mgi Gp, Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO2008007262A3 (en) * 2006-06-19 2008-08-14 Univ Do Porto Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity
US8350036B2 (en) 2006-06-19 2013-01-08 Universidade Do Porto Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity

Also Published As

Publication number Publication date
HRP950250A2 (en) 1997-10-31
SG73418A1 (en) 2000-06-20
CN1092185C (zh) 2002-10-09
IL113415A (en) 1999-11-30
IL113415A0 (en) 1995-07-31
ZA953379B (en) 1996-10-28
JPH09512539A (ja) 1997-12-16
TW307764B (enrdf_load_stackoverflow) 1997-06-11
CN1148851A (zh) 1997-04-30
CA2188833A1 (en) 1995-11-09
AU2306595A (en) 1995-11-29
EP0757676A1 (en) 1997-02-12

Similar Documents

Publication Publication Date Title
US5376664A (en) Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US5206249A (en) Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
US5789418A (en) Bis-naphthalimides for the treatment of cancer
US5703089A (en) Dihydrodibenzisoquinolinediones
US5086059A (en) Bis-naphthalimides as anticancer agents
GB1603228A (en) Indole derivatives a process for preparing them and pharmaceutical compositions containing them
WO1995029895A1 (en) Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents
AU604726B2 (en) Antiarrhythmic agent
US5461176A (en) Processes for preparing bis-naphthalimides containing amino-acid derived linkers
EP0662076B1 (en) 2-aminoalkyl-5-aminoalkylamino substituted isoquinoindazole-6-(2h)-ones with antitumour activity
WO1994003432A1 (en) Polyhydroxylated naphthyl 2-carboxylate, and quinolyl and isoquinolyl 3-carboxylate derivatives as protein tyrosine kinase inhibitors
US5329048A (en) Process of preparing tetraamino intermediates
US5359070A (en) Unsymmetrical bis-imides as anticancer agents
EP0639183A1 (en) Nitrogen oxides of aza- and diaza-anthracenedione derivatives, their preparation and their use as antitumor agents
JPH11513020A (ja) 抗腫瘍活性を有する新規ピリド−チオピラノインダゾール類
WO1994005641A1 (en) 4-SUBSTITUTED 6,9,-BIS (SUBSTITUTED-AMINO) BENZO [g] ISOQUINOLINE-5,10,DIONES
ITMI971850A1 (it) Derivati di pirazolo-acridine aventi attivita' antitumorale

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95193192.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR BY CA CN CZ FI HU JP KR KZ MX NO NZ PL RU SI UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995916636

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2188833

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1995916636

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995916636

Country of ref document: EP